INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.- SLNO

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product, Vykat XR, which led to a significant drop in the company's stock price [1][2]. Group 1: Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO [1]. - The company's only product, Vykat XR, has been criticized as overpriced and potentially unsafe for children according to a report by Scorpion Capital [2]. Group 2: Stock Performance - Following the publication of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, representing a decline of 7.41%, closing at $71.63 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].